Meeting
2023 ASCO Annual Meeting
Liquid-biopsy detection of FGFR2 and other actionable rearrangements in GI malignancies.
Authors
Pashtoon Murtaza Kasi
Weill Cornell Medicine, Englander Institute of Precision Medicine, New York Presbyterian Hospital, New York, NY
Pashtoon Murtaza Kasi , Jessica Kim Lee , Hanna Tukachinsky , Lincoln W Pasquina , Pierre Vanden Borre , Brennan James Decker , Dean C. Pavlick , Justin Allen , Christine Parachoniak , Alexa Betzig Schrock , Christine M. Lovly , Geoffrey R. Oxnard , Vivek Subbiah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4085)
DOI
10.1200/JCO.2023.41.16_suppl.4085
Abstract #
4085
Poster Bd #
406
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Circulating tumor DNA–based genomic landscape of KRAS wild-type pancreatic adenocarcinoma.
First Author: Brendon Fusco
Poster
2014 Gastrointestinal Cancers Symposium
Next-generation sequencing yields promising targets in advanced cholangiocarcinoma (CCA).
First Author: Rachna T. Shroff
Poster
2019 ASCO Annual Meeting
Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).
First Author: Milind M. Javle
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Novel potential mechanisms of acquired resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal cancer (CRC).
First Author: Christine Megerdichian Parseghian